期刊
ACTA NEUROLOGICA SCANDINAVICA
卷 122, 期 1, 页码 41-45出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1600-0404.2009.01253.x
关键词
BDNF G196A polymorphism; clinical manifestation; Parkinson's disease; risk factor
资金
- Juan March Foundation
- Marcelino Botin Foundation
- Spanish Ministry of Health
- Spanish Ministry of Education and Science
- Andalusian Government
- Fundacion Carolina/BBVA
Objectives - Parkinson's disease (PD) is characterized by the dopaminergic neuronal death in substantia nigra, and genetic factors appear to be involved in the pathophysiology of this disease. Brain-derived neurotrophic factor (BDNF) is widely expressed in the central nervous system and is necessary for the survival of dopaminergic neurons in substantia nigra. G196A, a common polymorphism of the BDNF gene, not only affects cognitive and motor processes, but also is associated with various psychiatric disorders. We evaluated whether G196A polymorphism is associated with PD and/or modifies clinical manifestations in PD patients. Methods - We included 193 PD patients and 300 control subjects. G196A polymorphism was screened by restriction fragment length polymorphism analysis. Clinical features of each patient were examined in detail. The possible association between genotype and clinical characteristics were determined by bivariate and multivariate analyses. Results - The distribution of G196A allele and genotype frequency was similar between PD and control subjects. Clinical characteristics, including Hoehn-Yahr stage, motor symptoms, non-motor symptoms (depression, cognitive dysfunction, psychiatric dysfunctions, and sleep behavior disorder), and dyskinesias, were not associated with this polymorphism. Conclusions - G196A polymorphism is not a risk factor for PD and does not seem to modify clinical features in PD patients studied here.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据